These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 35359087)
21. A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial. Ychou M; Rivoire M; Thezenas S; Quenet F; Delpero JR; Rebischung C; Letoublon C; Guimbaud R; Francois E; Ducreux M; Desseigne F; Fabre JM; Assenat E Ann Surg Oncol; 2013 Dec; 20(13):4289-97. PubMed ID: 23955585 [TBL] [Abstract][Full Text] [Related]
22. Selective intra-arterial chemotherapy with floxuridine as second- or third-line approach in patients with unresectable colorectal liver metastases. Samaras P; Breitenstein S; Haile SR; Stenner-Liewen F; Heinrich S; Feilchenfeldt J; Renner C; Knuth A; Pestalozzi BC; Clavien PA Ann Surg Oncol; 2011 Jul; 18(7):1924-31. PubMed ID: 21207165 [TBL] [Abstract][Full Text] [Related]
23. Secondary Metastases Resection After Bevacizumab Plus Irinotecan-Based Chemotherapy in First-Line Therapy of Metastatic Colorectal Cancer in a Real-Life Setting: Results of the ETNA Cohort. Rouyer M; Smith D; Laurent C; Becouarn Y; Guimbaud R; Michel P; Tubiana-Mathieu N; Balestra A; Jové J; Robinson P; Noize P; Moore N; Ravaud A; Fourrier-Réglat A; Target Oncol; 2016 Feb; 11(1):83-92. PubMed ID: 26298481 [TBL] [Abstract][Full Text] [Related]
24. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). Folprecht G; Gruenberger T; Bechstein W; Raab HR; Weitz J; Lordick F; Hartmann JT; Stoehlmacher-Williams J; Lang H; Trarbach T; Liersch T; Ockert D; Jaeger D; Steger U; Suedhoff T; Rentsch A; Köhne CH Ann Oncol; 2014 May; 25(5):1018-25. PubMed ID: 24585720 [TBL] [Abstract][Full Text] [Related]
25. [Analysis of factors related to the prognostic benefit of neoadjuvant chemotherapy followed by interval debulking surgery in patients with advanced ovarian cancer]. Wang DF; Zhang GN; Peng CR; Shi Y; Shi XW Zhonghua Fu Chan Ke Za Zhi; 2021 Jun; 56(6):385-392. PubMed ID: 34154313 [No Abstract] [Full Text] [Related]
26. [Evaluation value of preoperative peripheral blood lymphocyte-to-monocyte ratio on the prognosis of patients with stage III colon cancer]. Chen J; Peng J; Fan W; Zhang R; Wang F; Zhou W; Xu D; Pan Z; Lu Z Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):73-78. PubMed ID: 30703797 [TBL] [Abstract][Full Text] [Related]
27. Outcome of microscopic incomplete resection (R1) of colorectal liver metastases in the era of neoadjuvant chemotherapy. Ayez N; Lalmahomed ZS; Eggermont AM; Ijzermans JN; de Jonge J; van Montfort K; Verhoef C Ann Surg Oncol; 2012 May; 19(5):1618-27. PubMed ID: 22006375 [TBL] [Abstract][Full Text] [Related]
28. Effect of Time to Surgery of Colorectal Liver Metastases on Survival. Chen EY; Mayo SC; Sutton T; Kearney MR; Kardosh A; Vaccaro GM; Billingsley KG; Lopez CD J Gastrointest Cancer; 2021 Mar; 52(1):169-176. PubMed ID: 32086781 [TBL] [Abstract][Full Text] [Related]
29. Impact of Postoperative Infectious Complications on Long-Term Outcomes for Patients Undergoing Simultaneous Resection for Colorectal Cancer Liver Metastases: A Propensity Score Matching Analysis. Chen Q; Deng Y; Chen J; Zhao J; Bi X; Zhou J; Li Z; Huang Z; Zhang Y; Chen X; Zhao H; Cai J Front Oncol; 2021; 11():793653. PubMed ID: 35071001 [TBL] [Abstract][Full Text] [Related]
30. Chemotherapy Plus Bevacizumab as Neoadjuvant or Conversion Treatment in Patients with Colorectal Liver Metastases. García-Alfonso P; Cavanagh Podesta M; Muñoz Martín A; Blanco Codeisido M; Calvo A; Peligros I; Corcuera A; Belén Rúperez Blanco A; Custodio-Cabello S; López Trabada D; Martín M; DE Ramón E Anticancer Res; 2018 May; 38(5):3069-3077. PubMed ID: 29715142 [TBL] [Abstract][Full Text] [Related]
31. Changes in serum lactate dehydrogenase levels as markers of pathological response and prognosis in colorectal liver metastases patients receiving neoadjuvant chemotherapy followed by resection. Chen J; Chen Q; Yao J; Jiang Y; Zhou J; Zhao H; Cai J Ann Palliat Med; 2021 Oct; 10(10):10276-10292. PubMed ID: 34551571 [TBL] [Abstract][Full Text] [Related]
32. Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial. Mulcahy MF; Mahvash A; Pracht M; Montazeri AH; Bandula S; Martin RCG; Herrmann K; Brown E; Zuckerman D; Wilson G; Kim TY; Weaver A; Ross P; Harris WP; Graham J; Mills J; Yubero Esteban A; Johnson MS; Sofocleous CT; Padia SA; Lewandowski RJ; Garin E; Sinclair P; Salem R; J Clin Oncol; 2021 Dec; 39(35):3897-3907. PubMed ID: 34541864 [TBL] [Abstract][Full Text] [Related]
33. Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer. Tsuchihashi K; Ito M; Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama A; Denda T; Satake H; Suto T; Sugimoto N; Katsumata K; Ishikawa T; Kashiwada T; Oki E; Komatsu Y; Okuyama H; Sakai D; Ueno H; Tamura T; Yamashita K; Kishimoto J; Shimada Y; Baba E Clin Colorectal Cancer; 2018 Dec; 17(4):e687-e697. PubMed ID: 30149986 [TBL] [Abstract][Full Text] [Related]
34. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients]. Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471 [TBL] [Abstract][Full Text] [Related]
35. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients. Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645 [TBL] [Abstract][Full Text] [Related]
36. Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases. Pietrantonio F; Mazzaferro V; Miceli R; Cotsoglou C; Melotti F; Fanetti G; Perrone F; Biondani P; Muscarà C; Di Bartolomeo M; Coppa J; Maggi C; Milione M; Tamborini E; de Braud F Med Oncol; 2015 Jul; 32(7):182. PubMed ID: 26003673 [TBL] [Abstract][Full Text] [Related]
37. [A Propensity Score Matching Study of Autologous Hematopoietic Stem Cell Transplantation and New Drug Chemotherapy for Newly Diagnosed Multiple Myeloma]. Yang FY; Wang HF; Xia LH; Wang QQ; Qian CJ; He J Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):158-165. PubMed ID: 35123620 [TBL] [Abstract][Full Text] [Related]
38. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Adam R; Pascal G; Castaing D; Azoulay D; Delvart V; Paule B; Levi F; Bismuth H Ann Surg; 2004 Dec; 240(6):1052-61; discussion 1061-4. PubMed ID: 15570210 [TBL] [Abstract][Full Text] [Related]
39. [Prognostic analysis of neoadjuvant chemotherapy for locally advanced gastric cancer with propensity score matching method]. Peng L; Yang W; Zhang Z; Zhi C; Zhou X; Liu H; Hua Y Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Oct; 21(10):1148-1153. PubMed ID: 30370514 [TBL] [Abstract][Full Text] [Related]
40. [Comparison of the efficacy of irreversible electroporation and conversional resection for locally advanced pancreatic cancer]. He CB; Wang J; Mao YZ; Lao XM; Li SP Zhonghua Wai Ke Za Zhi; 2022 Oct; 60(10):948-954. PubMed ID: 36207984 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]